Research
Hormonal
AgRP neuron inhibition is a necessary mechanism for the appetite-suppressing effects of incretin-based obesity therapies (GLP-1 and GIP analogs).
This research confirms that GLP-1 and GIP medications (like Ozempic or Wegovy) work by directly inhibiting the brain's hunger-promoting neurons (AgRP). This neural inhibition is a key reason these drugs successfully suppress appetite.
GoodSupportsHIGH confidence
optogenetic stimulation of AgRP neurons partially attenuated incretin-induced feeding suppression, suggesting that AgRP neuron inhibition is necessary for the full appetite-suppressing effects of incretin-based therapeutics.
Why this rating
High-quality in vivo mouse data using fiber photometry and optogenetics, though not human clinical trials.
Source
Incretin hormones and pharmacomimetics rapidly inhibit AgRP neuron activity to suppress appetite
Hayley E. McMorrow et al. · bioRxiv (Cold Spring Harbor Laboratory) · 2024
DOI 10.1101/2024.03.18.585583
preprintCited 10×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →